Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

Keywords

Cabozantinib, Sorafenib, Hepatocellular carcinoma, Medicine, Oncology

References

• Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinomaLijun Zhou, X-D Liu, Mingli Sun — 2015
• Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012Jacques Ferlay, Isabelle Soerjomataram, Rajesh Dikshit — 2015
• Expression of hepatocyte growth factor and its receptor c‐met proto‐oncogene in hepatocellular carcinomaTakahiro Ueki, Jiro Fujimoto, Tatsuo Suzuki — 1997
• Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.Ann‐Lii Cheng, Yoon‐Koo Kang, Zhendong Chen — 2009
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).E. Eisenhauer, P. Therasse, Jan Bogaerts — 2009
• Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumorsBarbara Sennino, Toshina Ishiguro‐Oonuma, Ying Wei — 2012
• Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.Josep M. Llovet, Thomas Decaens, Jean‐Luc Raoul — 2013
• Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene.Selma Pennacchietti, Paolo Michieli, Laura Galluzzo — 2003
• Interim analysis: the alpha spending function approach.David L. DeMets, K. K. Gordon Lan — 1994
• The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancerDouglas K. Graham, Deborah DeRyckere, Kurtis D. Davies — 2014
• Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and METQingfeng Xiang, Weiqiang Chen, Meng Ren — 2014
• Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor GrowthF. Michael Yakes, Jason Chen, Jenny Tan — 2011
• HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors.Farbod Shojaei, Joseph H. Lee, Brett H. Simmons — 2010
• Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control.Hannah K. Weir — 2003
• The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached?Ghassan K. Abou‐Alfa, Alan P. Venook — 2013
• Cabozantinib versus everolimus in advanced renal cell carcinomaToni K. Choueiri, Bernard Escudier, Thomas Powles — 2015
• Elevated hepatocyte growth factor expression as an autocrine c‐Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cellsZeynep Fırtına Karagonlar, Doğukan Koç, Evin İşcan — 2016
• Annual Report to the Nation on the Status of Cancer, 1975–2012, Featuring the Increasing Incidence of Liver CancerA. Blythe Ryerson, Christie R. Eheman, Sean F. Altekruse — 2016
• Axl Expression Stratifies Patients with Poor Prognosis after Hepatectomy for Hepatocellular CarcinomaJian Liu, Kui Wang, Zhenlin Yan — 2016
• Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.Toni K. Choueiri, Bernard Escudier, Thomas Powles — 2016

Cited by

• The Role of Pharmacotherapy in Treatment of Meningioma: A Systematic Reviewshecanip — 2023
• HepatologyS. Atkinson, A. Dhar — 2008
• [New Systemic Therapies for Advanced Hepatocellular Carcinoma].Do Young Kim — 2019
• Biomarker-Driven and Molecular Targeted Therapies for Hepatobiliary Cancers.William Proctor Harris, Kit Man Wong, Supriya K. Saha — 2018
• Recent developments with immunotherapy for hepatocellular carcinomaOliver Waidmann — 2018
• Molecular therapies and precision medicine for hepatocellular carcinomaJosep M. Llovet, Robert Montal, Daniela Sia — 2018
• Beneficial and Paradoxical Roles of Anti-Oxidative Nutritional Support for Non-Alcoholic Fatty Liver DiseaseDaisuke Uchida, Akinobu Takaki, Takuya Adachi — 2018
• Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trialRoser Pinyol, Robert Montal, Laia Bassaganyas — 2018
• The Expanding Role of Systemic Therapy in the Management of Hepatocellular CarcinomaOmar Abdel‐Rahman, Winson Y. Cheung — 2018
• Changes in plasma interleukin-8 and tumor necrosis factor-α levels during the early treatment period as a predictor of the response to sorafenib in patients with unresectable hepatocellular carcinomaAyako Iida‐Ueno, Masaru Enomoto, Sawako Uchida‐Kobayashi — 2018
• Systemic Treatment of Advanced Hepatocellular Carcinoma in Older AdultsLuisa Marie Arellano, Sukeshi Patel Arora — 2018
• Systemic treatment for hepatocellular carcinomaManushi Aggarwal, Abeer Arain, Zhaohui Jin — 2018
• Lenvatinib as a therapy for unresectable hepatocellular carcinomaAndrea Spallanzani, Giulia Orsi, Kalliopi Andrikou — 2018
• The Role of Angiogenesis in Hepatocellular CarcinomaMichael A. Morse, Weijing Sun, Richard D. Kim — 2018
• HCC: Nach Sorafenib-Versagen verlängert Cabozantinib das ÜberlebenBeate Schumacher — 2018
• Molecular Scoring of Hepatocellular Carcinoma for Predicting Metastatic Recurrence and Requirements of Systemic ChemotherapyNaoshi Nishida, Takafumi Nishimura, Toshimi Kaido — 2018
• Targeted and Immune-based Therapies for Hepatocellular CarcinomaTim F. Greten, Chunwei W. Lai, Guangfu Li — 2018
• New Systemic Treatments in Advanced Hepatocellular CarcinomaMarco Sanduzzi‐Zamparelli, Álvaro Díaz‐González, María Reig — 2019
• New and old biomarkers of hepatocellular carcinomaGeorgios Zacharakis, Ahmad Aleid, Khaled K. Aldossari — 2018
• Recent advances in medical management of hepatocellular carcinomaKenji Ikeda — 2018

Related papers

• Interim analysis of the ACTION trial: Cabozantinib for hepatocellular carcinoma patients who discontinued first line treatment other than sorafenib or due to sorafenib intoleranceMarco Sanduzzi Zamparelli, Sergio Muñoz Martínez, Mariona Calvo — 2023
• Supplementary Data from Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue SarcomasGeraldine O’Sullivan Coyne, Shivaani Kummar, James Hu — 2023
• Supplementary Data from Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue SarcomasGeraldine O’Sullivan Coyne, Shivaani Kummar, James Hu — 2023
• Supplementary Data from Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue SarcomasGeraldine O’Sullivan Coyne, Shivaani Kummar, James Hu — 2023
• Supplementary Data from Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue SarcomasGeraldine O’Sullivan Coyne, Shivaani Kummar, James Hu — 2023
• Cabozantinib: a novel tyrosine kinase receptor inhibitor for the treatment for advanced renal cell carcinomaMayur Porwal — 2017
• Supplementary Data from Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue SarcomasGeraldine O’Sullivan Coyne, Shivaani Kummar, James Hu — 2023
• Cabozantinib Approved for Renal Cell Carcinoma.2016
• Activity of the oral multi-tyrosine kinase inhibitor cabozantinib (XL184, cabozantinib) in a gastrointestinal stromal tumor (GIST) xenograftThomas Van Looy, J Hemelaers, Agnieszka Woźniak — 2013